Fresenius picks up M&A pace with Akorn, Merck KGaA deals – Reuters


Reuters

Fresenius picks up M&A pace with Akorn, Merck KGaA deals
Reuters
The latest deals are in keeping with Fresenius’s focus on drugs that have lost patent protection, but also mark a foray into new dosage forms, therapeutic areas and biotech drugs for its Kabi unit, a maker of generic infusion drugs as well as tube
Fresenius snaps up Akorn, Merck KGaA’s biosimilars in separate dealsNasdaq

all 62 news articles »

Read More…

Share This: